Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.

@article{Thompson2006AssessingPC,
  title={Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.},
  author={Ian M. Thompson and Donna P. Ankerst and Chen Chi and Phyllis J. Goodman and Catherine M. Tangen and M. Scott Lucia and Ziding Feng and Howard L. Parnes and Charles Arthur Coltman},
  journal={Journal of the National Cancer Institute},
  year={2006},
  volume={98 8},
  pages={529-34}
}
BACKGROUND Prostate-specific antigen (PSA) testing is the primary method used to diagnose prostate cancer in the United States. Methods to integrate other risk factors associated with prostate cancer into individualized risk prediction are needed. We used prostate biopsy data from men who participated in the Prostate Cancer Prevention Trial (PCPT) to develop a predictive model of prostate cancer. METHODS We included 5519 men from the placebo group of the PCPT who underwent prostate biopsy… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS